SCHEMBL4859699

SCHEMBL4859699

CCc1ccc(C(=O)c2cnccc2Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HTT P42858 2/20 0.49
TRPV1 Q8NER1 1/20 0.46
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
PLK1 P53350 1/20 0.44
ALDH1A1 P00352 5/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
POLB P06746 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GAA P10253 3/20 0.41
LMNA P02545 1/20 0.41
AGTR1 P30556 1/20 0.41
CCR9 P51686 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4860187 0.83 SMN1; SMN2 (0.50) MAPTSMN1; SMN2HTTTRPV1PLK1
SCHEMBL1921967 0.82 ROCK2 (0.50) SMN1; SMN2HTTROCK2ROCK1RAB9A
SCHEMBL22492820 0.82 ROCK2 (0.57) MAPTSMN1; SMN2ROCK2ROCK1ALDH1A1
SCHEMBL4849875 0.80 SMN1; SMN2 (0.50) MAPTSMN1; SMN2HTTTRPV1PLK1
SCHEMBL5700207 0.79 KMT2A (0.55) MAPTSMN1; SMN2ROCK2ROCK1ALDH1A1
SCHEMBL9261793 0.76 KMT2A (0.50) MAPTROCK2ROCK1ALDH1A1RAB9A
SCHEMBL9259850 0.76 JAK2 (0.50) ROCK2ROCK1NPC1CNR2POLB
SCHEMBL9063310 0.75 GAA (0.59) MAPTSMN1; SMN2HTTPLK1ALDH1A1
SCHEMBL19148992 0.74 SRD5A2 (0.57) MAPTSMN1; SMN2HTTALDH1A1RAB9A
SCHEMBL21578901 0.74 ROCK2 (0.51) MAPTSMN1; SMN2ROCK2ROCK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 MAPT 1124/4885SMN1; SMN2 4397/4885HTT 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.